Imaging agent developer ImaginAb has signed a collaboration agreement with pharmaceutical companies AstraZeneca, Pfizer, and Takeda Pharmaceutical to further the clinical development of its CD8 PET technology.
The three firms will help guide a current clinical trial that's evaluating the utility and value of CD8 ImmunoPET in immuno-oncology drug development, according to ImaginAb. In exchange, they will receive early access to clinical and imaging data and be able to contribute to the post-trial data analysis, ImaginAb said.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
